PDCD1 and neoplasm: Pembrolizumab, a mAb that targets the programmed death receptor-1 (PD-1), is approved for treatment of solid tumors that are microsatellite unstable (MSI-H) or mismatch repair deficient (dMMR), independent of tumor site of origin (13, 14).